Author

Patrick Alexander Ott

Harvard UniversityORCID 0000-0002-4253-943XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Assay:proteomics· 1

Frequent Co-Authors

Brigette KobsiD· 1 shared Catherine J. WuiD· 1 shared Christine Guo LianiD· 1 shared David J. MooneyiD· 1 shared David KY Zhang· 1 shared David LiuiD· 1 shared Donna S NeubergiD· 1 shared Eliezer M. Van AlleniD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Brigette KobsORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Programmable antigen-presenting scaffolds expand rare tumor-antigen-specific T cells from peripheral blood

Jessica Nicole DeVilla, Yoav Binenbaum, Nicoletta Cieri, David KY Zhang, Helen Ji, Vittoria Martinolli D’Arcy, Giacomo Oliveira, Michael Manos, Donna S Neuberg, Jerome Ritz, Patrick Alexander Ott, David J. Mooney, Catherine J. Wu

This paper introduces APC-ms, a platform that expands rare tumor-antigen-specific T cells from peripheral blood, achieving higher enrichment and functional properties compared to conventional methods.

bioRxiv · Oct 8, 2026 · PreprintImmunology

Immunogenic tumor mass dormancy as a driver of persistent residual lesions in immunotherapy-treated melanoma

Yingxiao Shi, Zoltan Maliga, Tuulia Vallius, Shishir Mani Pant, Roxanne J. Pelletier, Brigette Kobs, Priyanka Solanky, Yiwen He, Eliezer M. Van Allen, Sandro Santagata, Patrick Alexander Ott, Christine Guo Lian, Elizabeth Iannotti Buchbinder, David Liu, Peter Karl Sorger

This study shows that immunogenic tumor mass dormancy, not cell-level quiescence, persists in residual melanoma lesions after immunotherapy, with active tumor cells and immune interactions.

bioRxiv · Jun 27, 2026 · PreprintCancer Biology